AbbVie presents long-term Rinvoq vitiligo data through week 76

AbbVie announced on October 1, 2026, late-breaking results from its ongoing Phase 3 Viti-Up-1 and Viti-Up-2 clinical trials evaluating Rinvoq (upadacitinib, 15 mg once daily) in non-segmental vitiligo. The data, presented at the European Academy of Dermatology and Venereology Congress in Vienna, Austria, showed continued facial and total body repigmentation through week 76.

Following an initial 48-week placebo-controlled stage, patients who continued on Rinvoq in an open-label extension saw higher response rates for facial repigmentation (F-VASI 75) and total body repigmentation (T-VASI 50). Across both Phase 3 trials, 614 participants aged 12 and older were randomized across 90 sites worldwide.

The company also shared 28-week findings from a phototherapy substudy involving 84 adults who had not reached total body repigmentation benchmarks at week 48. Patients receiving Rinvoq combined twice weekly with narrowband ultraviolet B phototherapy achieved numerically higher response rates than those on Rinvoq alone. Safety results through week 76 showed no new safety signals.

Rinvoq is already approved in the European Union for patients 12 and older with non-segmental vitiligo who are candidates for systemic therapy. Its application for the condition is currently under regulatory review by the US Food and Drug Administration.